We are fulfilling our mandate. As you know, we are updating our guidelines, in view of addressing some of the problems raised during our hearings. We believe that modernizing our guidelines will provide increased flexibility to pharmaceutical companies so that they can set slightly higher prices.
On February 12th, 2009. See this statement in context.